Infinity Pharmaceuticals, Inc. engages in the discovery and development of medicines for the treatment of cancer and related conditions. It is conducting an international Phase III registration study of its lead product candidate, retaspimycin hydrochloride (IPI-504), an intravenously-administered small molecule inhibitor of heat shock protein 90 (Hsp90), in patients with refractory gastrointestinal stromal tumors; and a Phase I/II clinical trial in patients with advanced non-small cell lung cancer. The company's developing products include IPI-504 in combination with Taxotere in Phase Ib clinical trial for patients with solid tumors; IPI-493, an orally-delivered inhibitor of Hsp90 for patients with advanced solid tumors in Phase I clinical trial; and IPI-926, a hedgehog pathway inhibitor for patients with advanced and/or metastatic solid tumors in Phase I clinical trial. Further, the company has a discovery program focusing on fatty acid amide hydrolase, an enzyme that degrades anandamide and is targeted for neuropathic pain; and developing compounds that target Bcl-2, or Bcl-2 and Bcl-xL anti-apoptotic proteins. Infinity Pharmaceuticals has strategic alliance agreements with Mundipharma International Corporation Limited and Purdue Pharmaceutical Products L.P. to develop and commercialize pharmaceutical products; and a product development and commercialization agreement with MedImmune, Inc. to develop and commercialize cancer drugs targeting Hsp90 and the hedgehog pathway.

Launched in 1982 with a single product, Pharmadass (through subsidiary HealthAid) sells more than 450 products: vitamins and minerals, beauty care items, weight-loss formulas, and aromatherapy oils. It also sells anti-smoking products, herbal cigarettes, anti-snoring spray, and such supplements as fish oils and bee products. Specialty lines focus on such areas as mood enhancement, women's health, the immune system, and vitality. Pharmadass products are found in about 4,000 pharmacies and health food stores in the UK and in 30 countries worldwide.

Merck was founded in 1668 as a pharmacy and is the oldest pharmaceutical business in the world. The Merck family owns about 70% of the company. Merck is leaving its mark on the global pharmaceutical market. Through a network of nearly 200 companies in over 60 countries, the Merck develops, makes, and sells pharmaceutical and chemical products for global consumption. Name-brand prescription drugs include treatments for cardiovascular disease, cancers, infertility, and neurological disorders; the company also makes over-the-counter pharmaceuticals. Aside from drugs, the firm makes specialty chemicals, including laboratory reagents and cosmetic ingredients, as well as liquid crystals for televisions.

Laboratorios Almirall can help patients with a lot of ailments. The pharmaceutical company develops, manufactures, and markets drugs for a wide range of conditions affecting the digestive, central nervous, respiratory, and cardiovascular systems. Products include ebastine (antihistamine), aceclofenac (anti-inflammatory), and almotriptan (anti-migraine drug). The company, which is the leading drugmaker in Spain, operates from offices in Europe and Mexico and markets its drugs in more than 70 countries. Laboratorios Almirall is currently focusing its research efforts on treating asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, and dermatological problems, among others.

Paladin Labs Inc. company's slate of prescription offerings includes drugs for urology, endocrinology, cancer, dermatology, neurology, and women's health. Among Paladin's key products are prostate cancer treatment Trelstar, testosterone deficiency drug Testim, and osteoarthritis therapy Pennsaid. The company also offers some over-the-counter (OTC) drugs in Canada, including emergency contraceptive Plan B. The company focuses on serving markets that are overlooked by larger pharmaceutical firms, typically by forming developing and marketing partnerships with other drugmakers.

Impax Laboratories, Inc. company was founded in 1993 and is headquartered in Hayward, California. mpax Laboratories, Inc. engages in the development and commercialization of bioequivalent and brand-name pharmaceuticals. It operates through two divisions, Global Pharmaceuticals and Impax Pharmaceutical. The Global Pharmaceuticals division develops, formulates, manufactures, and sells controlled release and specialty generic pharmaceutical products. This division offers generic prescription products directly to wholesalers and large retail drug chains; and generic over-the-counter and generic prescription products through unrelated third-party pharmaceutical entities. The Impax Pharmaceutical division develops proprietary brand pharmaceutical products that address central nervous system disorders, including Alzheimer's disease, attention deficit hyperactivity disorder, depression, epilepsy, migraines, multiple sclerosis, Parkinson's disease, and schizophrenia. As of March 10, 2009, the company marketed 70 generic pharmaceuticals representing dosage variations of 24 different pharmaceutical compounds through its Global Pharmaceuticals division, as well as 16 products representing dosage variations of 4 different pharmaceutical compounds through its alliance agreements partners. Impax Laboratories markets and sells its generic pharmaceutical prescription drug products in the continental United States of America and the Commonwealth of Puerto Rico. It has alliance agreements with Teva Pharmaceutical Industries, Ltd.; Wyeth; Schering-Plough Corporation; and DAVA Pharmaceuticals, Inc.

BTG plc company acquires patent rights to new technologies and licenses them to manufacturers around the globe. With a focus on biopharmaceuticals and medical products, BTG reviews prospective technologies developed by research institutions, universities, and companies around the globe. In addition, BTG helps raise venture capital for start-up businesses and creates ventures (often through partnerships) to exploit new technologies. Originally set up by the British government to protect and patent British inventions, BTG has helped bring to market such famous inventions as the hovercraft and magnetic resonance imaging (MRI).

When new drugs are tested, someone has to go first and Chiltern (Early Phase) Ltd. (formerly Drug Development Solutions) will help find that person. A contract research organization (CRO), the company specializes in bridging the gap between preclinical studies and the early stages of clinical trials in humans for drug candidates. Its clients include large multinational companies as well as small biotech startups. The company's facilities are based inside a major hospital with access to emergency medical care if needed. The company was spun off from the University of Dundee in 1982 and then acquired by CRO giant Chiltern International in 2008.

ARCA biopharma, Inc. (ARCA), formerly Nuvelo, Inc. is a biopharmaceutical company focused on developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA’s lead product candidate Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator is under review by the United States Food and Drug Administration (FDA), for chronic heart failure (HF). Gencaro is an oral tablet formulation, dosed twice daily. On January 27, 2009, Nuvelo, Inc. (Nuvelo) completed the merger with ARCA biopharma, Inc. (ABI). Pursuant to the Merger, Dawn Acquisition Sub, Inc. merged with and into ABI, with ABI continuing after the merger as the surviving company and a wholly owned subsidiary of Nuvelo. Pursuant to the Merger, ABI changed its name to ARCA biopharma Colorado, Inc. and Nuvelo changed its name to ARCA biopharma, Inc.

Glycotex wants to see such creatures as ulcers, bed sores, and sunburns put on the Australian endangered species list. The biopharmaceutical company researches and develops products based on molecular glucan receptors that trigger the healing process. Connective tissue repair, skin ulcers, and bone fractures are primary recovery fields for its glucan receptor products. Glycotex's lead product candidate, MG3601, is a topical treatment for ulcers, and it has completed Phase II clinical trials. Other therapeutic candidates include Glucocol and Glucoprime, active ingredients designed to treat tendon regeneration and topical needs, respectively. Its parent company, Novogen, owns 84% of Glycotex.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.